Probe to detect spread of breast cancer gets distribution boost

April 9, 2013, University of Houston
Probe to detect spread of breast cancer gets distribution boost
The highly sensitive SentiMag instrument and its associated Sienna+ tracer combine nanotechnology and advanced magnetic sensors, removing the need for radiation, speeding up the process and putting the detection of the sentinel lymph node directly in the hands of surgeons. Credit: Photo courtesy of Endomagnetics

A device co-developed by a University of Houston (UH) physicist to detect the spread of breast cancer and allow physicians to better plan intervention is extending its market reach, bringing it another step closer to clinical trials in the U.S.

The SentiMag is a novel intraoperative probe that enables surgeons to more effectively locate the sentinel lymph node – the first lymph node to which a tumor's metastasizing drain. The highly sensitive SentiMag instrument and its associated Sienna+ tracer combine nanotechnology and advanced . Their removes the need for radiation, speeds up the process and puts the detection of the directly in the hands of surgeons.

Co-developed by Audrius Brazdeikis, a research associate professor of physics in the College of Natural Sciences and Mathematics at UH, and his colleagues at the University College of London (UCL), the device has been in use for more than a year in Europe and will now be distributed in the Middle East and Africa. Brazdeikis says approval for use in the U.S. is not far behind.

This most recent development of distribution beyond Europe is the result of an agreement signed between Sysmex Europe GmbH, a leading international company designing and producing diagnostic solutions for medical laboratories worldwide, and Endomagnetics Ltd., a UH medical devices company. Brazdeikis, who heads the Biomedical Imaging Group at the Texas Center for Superconductivity at UH (TcSUH), formed Endomagnetics with physics professor Quentin Pankhurst and Simon Hattersley from UCL to bring their technology to the marketplace.

"The most rewarding aspect in this adventure has been taking our original idea and seeing it through to market introduction," Brazdeikis said. "The biggest challenge wasn't the technology or research or science, but actually developing collaborations across the science and business interface to make this commercialization happen."

Current protocol for locating the sentinel node involves injecting a radioactive isotope several hours before surgery, followed by the surgeon using a highly directional Geiger counter, called a gamma probe, in the operating room to locate the lymph node with the highest radioactivity. Alternately, the SentiMag from Endomagnetics uses a detection system based on magnetics rather than radiation, with the radioactive tracer being replaced by the magnetic nanoparticle tracer and the handheld magnetic sensor replacing the gamma probe.

"This new method requires a surgeon to simply inject the area around a tumor with the Sienna+ nanoparticle, wait 30 minutes for the tracer to accumulate in the and then scan the area of interest using the SentiMag probe to locate the sentinel nodes," Brazdeikis said. "In contrast to the radioactive tracer, a typical magnetic tracer has a shelf life of many months. There are no staff safety issues or disposal of radioactive waste, which lifts regulatory burdens. It also reduces overall cost for the hospital by improving surgery scheduling and, therefore, is more accessible to all patients."

Initially funded by the UK-Texas Bioscience Initiative, the SentiMag system is currently in use in eight European Union countries – the United Kingdom, Germany, Poland, France, Italy, Belgium, Holland and Switzerland. When used together with the injectable Sienna+ nanoparticle, SentiMag gives physicians the ability to better gauge the extent to which cancer has spread.

Sysmex being granted the exclusive right to provide sales and support for this revolutionary system across the European, Middle Eastern and African regions will provide a strong platform for further investment and growth. This is Endomagnetics' first multi-region agreement, and it promises to extend widely the clinical use of the company's technology.

"We are extremely pleased with initial customer feedback," said Eric Mayes, CEO of Endomagnetics. "Partnering with a group as strong as Sysmex gives us the geographic scope and customer support we need to really make an impact."

Explore further: Less invasive surgery detects residual breast cancer in lymph nodes after chemotherapy

Related Stories

Less invasive surgery detects residual breast cancer in lymph nodes after chemotherapy

December 5, 2012
Most patients whose breast cancer has spread to their lymph nodes have most of the lymph nodes in their armpit area removed after chemotherapy to see if any cancer remains. A study conducted through the American College of ...

Sentinel node biopsy safe, effective in head and neck melanomas

August 5, 2011
A common technique for determining whether melanoma has spread can be used safely and effectively even in tumors from the head and neck area, according to a new study from the University of Michigan Comprehensive Cancer Center.

New imaging agent enables better cancer detection, more accurate staging

March 20, 2013
Researchers at the University of California, San Diego School of Medicine have shown that a new imaging dye, designed and developed at UC San Diego Moores Cancer Center, is an effective agent in detecting and mapping cancers ...

'Hidden' cancer cells not a factor in early-stage breast cancer survival rates

July 26, 2011
A new study shows that removing lymph nodes due to the presence of occult, or microscopic, cancer cells found in the sentinel lymph node – the one closest to the tumor -- has no impact on survival outcomes of women with ...

Recommended for you

T-cells engineered to outsmart tumors induce clinical responses in relapsed Hodgkin lymphoma

January 16, 2018
WASHINGTON-(Jan. 16, 2018)-Tumors have come up with ingenious strategies that enable them to evade detection and destruction by the immune system. So, a research team that includes Children's National Health System clinician-researchers ...

Researchers identify new treatment target for melanoma

January 16, 2018
Researchers in the Perelman School of Medicine at the University of Pennsylvania have identified a new therapeutic target for the treatment of melanoma. For decades, research has associated female sex and a history of previous ...

More evidence of link between severe gum disease and cancer risk

January 16, 2018
Data collected during a long-term health study provides additional evidence for a link between increased risk of cancer in individuals with advanced gum disease, according to a new collaborative study led by epidemiologists ...

Researchers develop a remote-controlled cancer immunotherapy system

January 15, 2018
A team of researchers has developed an ultrasound-based system that can non-invasively and remotely control genetic processes in live immune T cells so that they recognize and kill cancer cells.

Dietary fat, changes in fat metabolism may promote prostate cancer metastasis

January 15, 2018
Prostate tumors tend to be what scientists call "indolent" - so slow-growing and self-contained that many affected men die with prostate cancer, not of it. But for the percentage of men whose prostate tumors metastasize, ...

Pancreatic tumors may require a one-two-three punch

January 15, 2018
One of the many difficult things about pancreatic cancer is that tumors are resistant to most treatments because of their unique density and cell composition. However, in a new Wilmot Cancer Institute study, scientists discovered ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.